B. Metzler Seel. Sohn & Co. Holding Ag Ultragenyx Pharmaceutical Inc. Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Holding Ag transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Holding Ag holds 23,817 shares of RARE stock, worth $1.05 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,817Holding current value
$1.05 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
325Shares Held
85.6MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$440 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$248 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$226 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$184 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$136 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.1B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...